1. South Korea Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
BLUEMTEC CO. LTD.

BLUEMTEC CO. LTD.

KKRX:439580
2,130.00
KRW
-145.00
(-6.37%)
124.46EPS
15.32P/E
64.55BMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1,089.98
2,973.4
3,777.38
4,293.96
4,065.42
5,532.65
6,062.76
Basic EPS, GAAP
-23.33
-436.67
-697
-88.33
-146.47
-134.3
124.48
Free Cash Flow per Basic Share
-162.56
-591.67
-463.29
-824.83
-450.11
90.49
-39.19
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-21.44
-204.98
37.02
1,421.4
1,406.63
1,324.79
1,439.76
Tangible Book Value per Share
-21.8
-205.76
36.48
1,420.49
1,382.65
1,302.7
1,416.98
Basic Weighted Avg Shares
27
17
20
27
33
34
34
Sales/Revenue/Turnover
29,951
51,873
77,147
113,853
133,286
185,905
205,083
Operating Margin (%)
-1.14
-5.23
1.15
1.18
-5.17
-1.06
-0.34
Depreciation Expense
117
252
362
716
1,827
2,488
2,223
Net Income, GAAP
-641
-7,618
-14,235
-2,342
-4,802
-4,513
4,211
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-2.14
-14.69
-18.45
-2.06
-3.6
-2.43
2.05
Working Capital
-1,615
-13,500
-12,555
11,990
-8,431
-16,216
-14,928
LT Debt
2,644
3,026
6,672
9,227
12,354
8,671
8,166
Total Equity
-682
-6,339
1,178
45,415
47,137
44,839
48,731
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-0.8
Return on Capital (%)
- -
- -
- -
- -
- -
- -
4.79
Return on Common Equity (%)
- -
- -
- -
-10.05
-10.38
-9.81
9.17

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
32,671
33,015
33,424
LT Borrowings
800
800
700
LT Finance Leases
7,871
7,642
7,466
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
34
Market Capitalization
149,602
112,540
64,545

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
39,808
37,510
40,504
Cash, Cash Equivalents & STI
16,280
19,771
12,254
Accounts Receivable, Net
4,344
- -
3,185
Inventories
12,631
11,487
14,501
Total Current Liabilities
56,024
56,986
55,432
Payables & Accruals
- -
- -
- -
ST Debt
32,671
33,015
33,424
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
892.9%
-4.87%
Free Cash Flow
- -
20.15%
-120.6%
Net Income, GAAP
- -
238.09%
-6.03%
Sales/Revenue/Turnover
- -
45.21%
39.48%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
27,630
25,624
47,131
32,901
133,286
2025
34,175
45,650
52,137
53,943
185,905
2026
44,036
54,967
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-47.25
75.33
-104.33
-57.98
-146.47
2025
-16
-74
-14.53
2.35
-134.3
2026
78.07
58
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jun-Seok Kim
Full Time Employees
98
Sector
Distribution services
Industry
Medical distributors
Address
Pyeongtaek-si South Korea
IPO Date
Dec 13, 2023
Website
bluemtec.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
BLUEMTEC CO., LTD. is a South Korea-based healthcare technology and pharmaceutical distribution company that provides business-to-business (B2B) digital commerce platforms and integrated logistics solutions for hospitals, clinics, and pharmacies. The company operates an end-to-end digital ecosystem that modernizes the healthcare supply chain, offering a comprehensive suite of products and services that includes: BluePharmKorea, an online B2B marketplace distributing ethical pharmaceuticals (ETC), over-the-counter (OTC) drugs, vaccines, aesthetic medical products including botulinum toxins and dermal fillers, medical equipment, and clinical consumables; KuhlPharm, a specialized online procurement platform serving retail community pharmacies; BlueLogis, a cold-chain logistics and third-party fulfillment service providing temperature-controlled warehousing, automated inventory management, and pharmaceutical-grade delivery; BlueDoc, a digital recruitment, staffing, and community platform for healthcare professionals; BlueLabs, an in-house information technology and data intelligence division that develops e-commerce infrastructure, automated ordering tools, and healthcare analytics; and healthcare digital marketing services, providing global and domestic pharmaceutical manufacturers with web-based symposium hosting, targeted medical advertising, and customer engagement solutions. Founded in March 2015 as BluePharmKorea and rebranded to BLUEMTEC Co., Ltd. in July 2018, the company is headquartered in Pyeongtaek, Gyeonggi Province, South Korea, with primary operations spanning the domestic market. In recent corporate developments, BLUEMTEC has pursued strategic investments and commercial alliances to enhance its distribution infrastructure and service portfolio: the company acquired a 17.0% equity stake in medical network platform Medistaff in March 2024; acquired a 30.9% stake in specialized pharmaceutical logistics firm Gonggam Plus in June 2024 to reinforce its nationwide cold-chain network; secured a 16.4% equity stake in telehealth platform MDsquare in November 2024; entered a strategic partnership with Humedix in April 2025 to expand its aesthetic treatment distribution; signed an exclusive distribution agreement with Bioplus in April 2026 covering dermal fillers and skin booster portfolios; and approved an KRW 8 billion bond with warrants (BW) issuance in June 2026 to optimize its capital structure and finance ongoing operational growth.